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ABSTRACT
Objective: The objective of the study was to study various renal manifestations in sickle cell disease (SCD) and to establish a cause and effect 
relationship with the evaluation of risk factors.
Methods: This prospective observational cross-sectional study was conducted on 82 SCD patients belonging to the age group of 15–50 years of 
both the genders over a period of 2 years from January 2019 to December 2020 in MKCG Medical College and Hospital, Berhampur, Odisha, India. 
Eighty-two patients, 32 (39.02%) having sickle cell anemia (SCA) and 50 (60.98%) having sickle cell trait (SCT), admitted to medicine and nephrology 
wards of the hospital were included in this study. SCD patients with other hemolytic anemia and with renal congenital/structural abnormality and 
patients with systemic diseases such as diabetes mellitus, systemic hypertension, and systemic lupus erythematosus were excluded from the study. 
Various laboratory investigations such as complete blood count, hemoglobin (Hb), serum sodium, serum potassium, serum urea, serum creatinine, 
fasting blood sugar, erythrocyte sedimentation rate, liver function test, urine routine, and microscopic test were carried out. Diagnosis of SCD patients 
was based on sickling test and high-performance liquid chromatography testing. Radiologic imaging (Sonography for renal changes) was done at 
radiodiagnosis department of the hospital.
Results: Glomerular and tubular dysfunction was more in SCA (Hb SS) patients than SCT (Hb AS) patients and the abnormality was more in patients 
in crisis. Albuminuria in 78.12%, hematuria in 46.87%, cast and crystal in 28.12%, epithelial cell in 31.25%, and hyposthenuria in 56.25% were found 
in SCA patients. In SCT patients, albuminuria in 38%, hematuria in 16%, cast and crystal in 22%, epithelial cell in 12%, and hyposthenuria in 24% 
were found. All the above findings were more in percentages in crisis patients of both the groups. In SCA, 37.5% and in SCT, 2% were found to have 
chronic kidney disease.
Conclusion: Renal involvement in the form of glomerular and tubular dysfunction occur in SCD and more in crisis patients, leading to renal 
complications, and end-stage renal disease.
Keywords: Sickle cell disease, Sickle cell anemia, Sickle cell trait, Chronic kidney disease.
INTRODUCTION
Sickle cell disease (SCD) is an autosomal recessive hemoglobin disorder, 
predominantly affecting persons of African, Mediterranean, Indian and 
Middle Eastern descent. It occurs due to replacement of glutamic acid 
for valine at the sixth amino acid of the beta-globin chain. This mutation 
results in hemoglobin S (Hb S) tetramers that accumulate during tissue 
hypoxia, oxidative stress, or dehydration. The accumulation leads to red 
blood cell sickling, early destruction of erythrocytes, and wide spread 
vaso-occlusive episodes, subsequently resulting in multi organ damage.
SCD was first discovered in West Africa. An estimated seven percent of the 
world population carry an abnormal hemoglobin gene, while about three 
lakhs to five lakhs are born annually with significant hemoglobin disorder. 
Sickle cell syndrome is more frequent and constitutes 70% of affected 
births worldwide, the rest are due to thalassemias [1]. SCD affects many 
communities in India in certain regions, such as Central India (Deccan 
Region) and states of Gujarat, Maharashtra, and Kerala. The carrier 
frequency of the sickle cell gene varies from one percent to 35% and 
hence there are a huge number of SCD [2].
It has been observed that 11.1% in hospital patients of Western Odisha 
were sickle cell positive and the gene was found to be widespread in 
the state [3]. Renal complications, collectively known as sickle cell 
nephropathy (SCN), are among the most common complications of SCD 
and are the well-known cause of morbidity and mortality in SCD and the 
incidence of renal failure increases as patient survival improves, thus 
being a great challenge to the health care professionals of providing 
adequate services for treatment of SCD. SCN includes hematuria, 
proteinuria, hyposthenuria, renal papillary necrosis, renal tubular 
disorders, acute and chronic kidney injury, sickle cell glomerulopathy, 
and renal medullary carcinoma. Clinically significant renal involvement 
occurs more frequently in sickle cell anemia (SCA) than in sickle cell 
trait (SCT) or in combined hemoglobinopathies, except renal medullary 
carcinoma, which appears to be more common among SCT patients [4]. 
Platt et al. provided the most comprehensive analysis on life expectancy 
and risk factors for early death in SCD; 18% of deaths are ascribed to 
chronic end-organ involvement, predominantly renal [5].
Considering the magnitude of the SCD patients in this part of the 
country and as very few studies have been done in our region on SCN, it 
was considered worthwhile to undertake this present study for a better 
understanding of renal changes that may be found in SCD patients. The 
objective of this study was to evaluate various renal manifestations in 
SCD and to establish a cause and effect relationship with risk factors.
METHODS
A prospective observational cross-sectional study was designed in the 
Department of General Medicine and Nephrology in MKCG Medical 
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College and Hospital, Berhampur, Odisha, India over a period of 2 years 
from January 2019 to December 2020. A total number of 82 SCD 
patients belonging to the age group of 15–50 years of both the genders 
admitted to Medicine and Nephrology wards and diagnosed as a case of 
SCA (n=32; 39.02%) or SCT (n=50; 60.98%) according to clinical and 
hematological investigation fulfilling the inclusion, exclusion criteria 
were taken for the study.
Inclusion criteria
All patients with SCA or SCT, admitted in the departments of medicine 
and nephrology were included in this study.
Exclusion criteria
SCD patients with other hemolytic anemia and with renal 
congenital/structural abnormality and patients with systemic disease 
such as diabetes mellitus, systemic hypertension, and systemic lupus 
erythematosus were excluded from the study.
The study was conducted after the study protocol was approved by 
the Institutional Ethics Committee (No 765/Chairman-IEC, MKCG 
Medical college, Brahmapur-4). Informed consent was obtained from 
all the patients in accordance with the guidelines of the Declaration 
of Helsinki 2008. Patients were screened based on inclusion and 
exclusion criteria and selected patients were thoroughly examined. 
The evaluation was comprised detailed history, physical examination, 
and relevant investigations. Height, weight, and BMI were measured 
for every patient. Various laboratory investigations such as complete 
blood count, Hb, serum sodium, serum potassium, serum urea, serum 
creatinine, fasting blood sugar, erythrocyte sedimentation rate, liver 
function test, and urine routine microscopic test were done at Regional 
Diagnostic Centre of our hospital. Patients were diagnosed SCD based 
on sickling test and high-performance liquid chromatography testing.
Radiologic imaging (Sonography for renal changes) was done at 
Radiodiagnosis department of the hospital. The acute changes in the 
kidney were examined with ultrasound. Computed tomography and 
magnetic resonance imaging were used for the follow-up examinations. 
In evaluation of the acute changes in the kidney, the echogenicity of the 
renal structure, the delineation of the kidney, the renal vascularity, kidney 
size, and focal abnormalities were observed. Ultrasound was useful for 
diagnostic and prognostic purposes in chronic kidney disease (CKD).
In the present study, estimated glomerular filtration rate (eGFR) 
was assessed separately in adults and adolescents (<17 years) using 
CKD-EPI equation (2009) and Schwartz equation (2009), respectively.
eGFR (CKD-EPI equation, 2009):
eGFR = 141×min (SCr/K, 1)α×max (SCr/K, 1)−1.209×0.993Age×1.018 
[if female]
=141×min (SCr/K, 1)α×max (SCr/K, 1)-1.209×0.993Age×1.159 [if black]
Abbreviations/Units:
eGFR: Estimated glomerular filtration rate (ml/min/1.73 m2)
SCr: Standardized serum creatinine (mg/dL)
K=0.7 (females) or 0.9 (males)
α=–0.329 (females) or –0.411(males)
min: indicates the minimum of SCr/K or 1
max: indicates the maximum of SCr/K or 1
Age: in years
Schwartz equation (2009):
eGFR = 0.413×(Height/SCr) (height is expressed in centimeter)
CKD was diagnosed and classified according to 2012 kidney disease 
improving global outcomes criteria. Patients with persistent urinary 
anomalies or decreased eGFR at 3 months were considered to have CKD.
a. Stage 1: Normal; eGFR >90 ml/min/1.73 m2
b. Stage 2: Mild kidney damage; eGFR=60–89 ml/min/1.73 m2
c. Stage 3: Moderate kidney damage; eGFR=30–59 ml/min/1.73 m2
d. Stage 4: Severe kidney damage; eGFR=15–29 ml/min/1.73 m2
e.	 Stage	5:	Kidney	failure;	eGFR	≤15	ml/min/1.73	m2
Further, patients with eGFR >140 ml/min/1.73m2 are denoted as 
glomerular hyperfiltration, eGFR <89 to 60 ml/min/1.73m2 as renal 
insufficiency (RI) and eGFR <59 ml/min/1.73m2 as renal failure (RF).
Statistical analysis
Data were entered using Microsoft Excel and all statistical analysis was 
performed using Statistical Package for the Social Sciences, version 17.0. 
Basic descriptive statistics were computed for the demographic data. 
Values were expressed as mean±(SD)/or proportion (percentage) with 
statistical significance set at p-value <0.05 (p<0.05) was considered 
statistically significant, p<0.01 was highly significant, and p<0.001 was 
very highly significant.
RESULTS
Maximum number of cases was clustered in the age group of 15–25 years 
(58.54%), followed by in the age group of 26–35 years (26.97%). There 
were only 9 (10.98%) cases in the age group of 36–45 years. Among 
them, one case (1.22%) was SCA and eight cases (9.76%) were SCT. 
There was only one case above age 45 years that belong to SCT (Table 1). 
The result was statistically highly significant (p=0.009) (Table 1).
Out of total 32 males, maximum numbers (n=17, 53.12%) were in the 
age group of 15–25 years, and out of total 50 females, and maximum 
numbers (n=31, 62.01%) were also in the age group of 15–25 years. 
p-value of the above table data is 0.57 and is non-significant (Table 2).
Out of 82 cases of SCD patients, 21 patients presented with sickle cell 
crisis were studied. Male: female ratio in total study population with 
crisis was 0.4:1, that is, six cases (28.57%) were males and 15 cases 
(71.42%) were females. In AS pattern with crisis 7 cases (77.78%) out 
of nine cases were females, also in SS pattern with crisis maximum 
number of cases, 8 cases (66.66%) were females out of 12 cases.
Out of 21 patients of sickle cell crisis, maximum number of patients, 
14 patients (66.67%) were in the age group of 15–25 years followed 
by four patients (19.04%) in the age group of 26–35 years. In the SCT 
patients with crisis equal number of cases, that is, 3 each (33.33%) were 
in the age group of 15–25, 26–35, and 36–45 years. Among 12 patients 
of SS pattern with crisis, maximum number of cases 8 cases (66.66%) 
was females and they were in the age group of 15–25 years (Table 3).
Among the SCA patients, majority of the participants 19 (59.37%) had 
Hb level of range 5–7 g/dl and for SCT, majority 20 (40%) had Hb of level 
7–9 g/dl. The difference of Hb level among two groups was found to be 
very highly significant (p<0.001) (Table 4). Among the SCA the mean Hb 
level was 6.3 (±0.89) g/dl and for SCT it was 9 (±0.48) g/dl (Fig. 1).




SCA (%) SCT (%) Total (%) p‑value
15–25 26 (31.71) 22 (26.83) 48 (58.54) 0.009**
26–35 5 (6.10) 19 (23.17) 24 (29.27)
36–45 1 (1.22) 8 (9.76) 9 (10.98)
46–50 0 (0.00) 1 (1.22) 1 (1.22)
Total 32 (39.02) 50 (60.98) 82 (100.00)
*Significant at P<0.05, **Highly significant at P<0.01, ***Very highly significant 
at P<0.001, SCD: Sickle cell disease, SCA: Sickle cell anemia, SCT: Sickle cell trait










15–25 48 (58.5) 31 (62.0) 17 (53.1) 0.57
26–35 24 (29.3) 14 (28.0) 10 (31.2)
36–45 9 (11.0) 4 (8.0) 5 (15.6)
46–50 1 (1.2) 1 (2.0) 0 (0.0)
*Significant at P<0.05, **Highly significant at P<0.01, ***Very highly significant 
at P<0.001
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In Table 5, it was found that maximum number of female 
cases (n=19, 38%) was having low Hb level 5–7 g/dl. Maximum number 
of male cases (n=14, 43.8%) had Hb level 7–9 g/dl.
The major clinical symptoms among the study participants were 
fatigability, dyspnea, pallor, and icterus. Out of 82 participants, 
41 (50%) complained of fatigability, 21 (25.6%) complained of dyspnea, 
and 23 (28.0%) were having icterus. Nearly all participants had pallor. 
There were significant differences between SCA and SCT with respect 
to clinical symptoms such as fatigability, dyspnea, and icterus. Out of 32 
SCA patients, 27 (84.4%) complained of fatigability and out of 50 SCT 
patients, 14 (28.0%) had fatigability. This difference was statistically 
very highly significant (p<0.001) (Table 6).
Similarly, 13 (40.6%) out of 32 patients of SCA and eight (16.0%) out 
of 50 patients of SCT were having dyspnea as the clinical symptoms. 
This difference was found to be statistically highly significant (p<0.013) 
(Table 6). Icterus was seen among 16 (50.0%) patients of SCA and seven 
(14.0%) of SCT patients. This difference was found to be statistically 
very highly significant (p<0.001) (Table 6 and Fig. 2).
In SCA, 16 (50%) cases had microalbuminuria and nine (28.1%) cases 
had macroalbuminuria. In SCT, 12 (24%) cases had microalbuminuria 
and seven (14%) cases had macroalbuminuria among these data 
microalbuminuria shows significant p-value (0.015) when compared 
between SCA and SCT patients (Table 7).
Microscopic	 hematuria	 was	 a	 predominant	 finding	 in	 patients	 of	 SS	
pattern, that is, 15 cases (46.87%) of total 32 cases. On the other hand, 
among the patients with AS pattern eight cases (16%) had hematuria.
This data were significant having p-value <0.05 (Table 7).
Similarly cast and crystals in urine were found in nine cases (28.12%) 
of SS pattern and 11 cases (22%) of AS pattern. Out of total population, 
eight patients (9.7%) had RBC casts, while 18 patients (21.95%) had 
granular	casts.	Five	cases	(15.6%)	of	SS	pattern	had	significant	number	
of pus cells in their urine. Ten cases (31.2%) of SS pattern and six cases 
(12%) of AS pattern had epithelial cells in urine (Table 7).
Two cases (22.2%) of SCT pattern and 11 cases (91.9%) of SCA pattern 
with crisis had hematuria. This data show a p value of 0.001 and is 
highly significant. Out of 21 patients with sickle cell crisis, ten cases 
(48%)	had	significant	albuminuria,	out	of	which	one	case	(10%)	was	of	
SCT pattern with crisis and nine cases (90%) were of SCA pattern with 
crisis. For microalbuminuria the data has significant p-value (0.027). 
Nine cases (100%) of SCT pattern with crisis had casts and crystals in 
urine. There were six cases (50%) of SS pattern with crisis who had 
casts and crystals. Casts were mostly granular cast, followed by RBC 
casts (p-value=0.01). This data have statistical significance showing 
cast and crystals found more in urine in patients of SCA with crisis. 
There were seven cases (58.3%) of SCA pattern with crisis who had 
tubular epithelial cells in their urine microscopy, suggesting tubular 
damage; while none of the patients of SCT pattern with crisis had 
tubular epithelium in their urine microscopy (p=0.001) and is highly 
significant (Table 8). In SCA patients five (41.7%) cases had pus cells in 
urine while none of the SCT patients had pus cells.
Out	of	82	SCD	patients,	42	patients	(51.2%)	had	normal	urinary	specific	
gravity,	while	40	patients	(48.8%)	had	abnormal	urinary	specific	gravity.	
18 (56.2%) patients of SCA pattern had hyposthenuria and 12 (24.0%) 
patients of SCT pattern had hyposthenuria. Seven (21.9%) patients of 
SCA pattern had hypersthenuria and three (6.0%) of SCT pattern had 
hypersthenuria, (p<0.001) and is very highly significant (Table 9).
In 21 patients with sickle cell crisis nine (42.9%) had developed 
hyposthenuria out of which two cases (22.2%) were SCT patients and 
seven cases (58.33%) were SCA patients, p-value=0.019, suggesting 
significant data (Table 10).
In this study, 12 (37.5%) cases of SCA were found to have CKD and one 
(2%) case of SCT has CKD. This data show a p-value of <0.001 and are 
very highly significant (Table 11 and Fig. 3).
Seven (58.3%) cases of SCA patients with crisis and one (11.12%) case 
of SCT patients with crisis were found to have CKD by that time. Also 
highly significant p-value in relation to CKD in patients of SCA and SCT 
with crisis was found to be 0.027 (Table 12 and Fig. 4).
DISCUSSION
Advances in epidemiologic and genetic research in SCD have 
made it possible to understand the sickle-Hb-related nephropathy 
comprehensibly and thereby helping the individuals with sickle 
hemoglobinopathies. This study was made to determine the prevalence 
of CKD amongst patients with SCD and risk factor contributing to its 
development.
All cases belonging to the present study were in the age group of 
15–50 years with mean age of 25.28±8.93 years. Maximum number of 
cases was clustered in the age group of 15–25 years which correlates 
well with the demographic pattern of our country and with some other 
Table 3: Age‑ and gender‑wise distribution of patients with sickle cell crisis
Age Groups SCA (%) SCT (%) Overall (%)
Female (n=8) Male (n=4) Female (n=7) Male (n=2) Female (n=15) Male (n=6)
15–25 8 (100) 3 (75.0) 2 (28.6) 1 (50.0) 10 (66.7) 4 (66.7)
26–35 0 (0) 1 (25.0) 3 (42.9) 0 (0) 3 (20.0) 1 (16.7)
36–45 0 (0) 0 (0) 2 (28.6) 1 (50.0) 2 (13.3) 1 (16.7)
46–50 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
SCA: Sickle cell anemia, SCT: Sickle cell trait
Table 4: Anemia in patients with SCD
Hb level SCA (n=32) (%) SCT (n=50) (%) p‑value
>9 g/dl 1 (3.12) 18 (36) <0.001***
7–9 g/dl 12 (37.5) 20 (40)
5–7 g/dl 19 (59.37) 12 (24)
*Significant at P<0.05, **Highly significant at P<0.01, ***Very highly significant 
at P<0.001, Hb: Hemoglobin, SCA: Sickle cell anemia, SCT: Sickle cell trait, 
SCD: Sickle cell disease,
Fig. 1: Mean hemoglobin between two groups of sickle cell disease
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findings in the previous studies such as Khan and Patil, Andhale et al., 
and Dhumne and Jawade [6-8]. There was low prevalence of SCD in 
higher age group due to the small sample size and the fact that most of 
the sickle cell patients succumbed in early ages due to the disease [6]. 
But in countries with access to organized healthcare, survival of children 
with SCD has greatly improved resulting in a growing population of 
adults with SCD [9].
Male: female ratio in the present study population was 0.64:1, while that 
of SCA pattern and SCT pattern were 0.88:1 and 0.51:1, respectively. This 
shows a similarity with others’ findings [6-8]. Majority of the cases had 
clinical features of fatigability, dyspnea, joint pain, pallor, icterus, and 
edema. Pallor was seen in all (100%) patients. Between two groups, 
fatigability, dyspnea, and icterus were seen more in SCA patients as 
compared to SCT patients. All these findings were found to be statistically 
significant (p<0.05). According to symptoms and related signs these are 
more common in SCA than SCT because SCA is more severe than SCT.
Among the SCA patients, majority of the participants (59.37%) had 
Hb level of range 5–7 g/dl and for SCT, majority (40%) had Hb level 
of 7–9 g/dl. The difference of Hb level among two groups was found 
to be very highly significant (p<0.001). Among the SCA, the mean Hb 
level was 6.35 (±0.89) and for SCT it was 9 (±0.48) indicating a lower 
average Hb in SCA groups. Analysis of the above data shows Hb was 
found to be on lower side among patients of SCA than SCT, p<0.001 and 















4 (33.3) 1 (11.1) 5 (23.8) 0.019*
Hyposthenuria 
(<1.015)
7 (58.3) 2 (22.2) 9 (42.9)
*Significant at P<0.05, **Highly significant at P<0.01, ***Very highly significant 
at P<0.001, SCA: Sickle cell anemia, SCT: Sickle cell trait
















7 (21.9) 3 (6.0) 10 (12.2) <0.001***
Hyposthenuria 
(<1.015)
18 (56.2) 12 (24.0) 30 (36.6)
*Significant at P<0.05, **Highly significant at P<0.01, ***Very highly significant 
at P<0.001, SCA: Sickle cell anemia, SCT: Sickle cell trait
Table 7: Physical and microscopic urine analysis of the study 












No 16 (50.0) 38 (76.0) 54 (65.9)
Yes 16 (50.0) 12 (24.0) 28 (34.1)
Macro-albuminuria 0.115
No 23 (71.9) 43 (86.0) 66 (80.5)
Yes 9 (28.1) 7 (14.0) 16 (19.5)
Hematuria 0.002**
No 17 (53.1) 42 (84.0) 59 (80.5)
Yes 15 (46.8) 8 (16.0) 23 (19.5)
Cast and crystals in urine 0.297
Granular 4 (12.5) 8 (16.0) 12 (14.6)
No 23 (71.9) 39 (78.0) 62 (75.6)
RBC 2 (6.2) 0 (0.0) 2 (2.4)
RBC and Granular 3 (9.4) 3 (6.0) 6 (7.3)
Epithelial cells 0.032*
No 22 (68.8) 44 (88.0) 66 (80.5)
Yes 10 (31.2) 6 (12.0) 16 (19.5)
Pus cells 0.004**
No 27 (84.4) 50 (100.0) 77 (93.9)
Yes 5 (15.6) 0 (0.0) 5 (6.1)
*Significant at P<0.05, **Highly significant at P<0.01, ***Very highly significant 
at P<0.001, SCA: Sickle cell anemia, SCT: Sickle cell trait, RBC: Red blood cell













No 7 (58.3) 9 (100.0) 16 (76.2)
Yes 5 (41.7) 0 (0.0) 5 (23.8)
Macro-albuminuria 0.237
No 8 (66.7) 8 (88.9) 16 (76.2)
Yes 4 (33.3) 1 (11.1) 5 (23.8)
Hematuria 0.001**
No 1 (8.3) 7 (77.8) 8 (38.1)
yes 11 (91.7) 2 (22.2) 13 (61.9)
Cast and crystals in urine 0.01*
Granular 1 (8.3) 4 (44.4) 5 (23.8)
No 6 (50.0) 2 (22.2) 8 (38.1)
RBC 2 (16.7) 0 (0.0) 2 (9.5)
RBC and Granular 3 (25.0) 3 (33.3) 6 (28.6)
Epithelial cells 0.005**
No 5 (41.7) 9 (100.0) 14 (66.7)
Yes 7 (58.3) 0 (0.0) 7 (33.3)
Pus Cells 0.027*
No 7 (58.3) 9 (100.0) 16 (76.2)
Yes 5 (41.7) 0 (0.0) 5 (23.8)
*Significant at P<0.05, **Highly significant at P<0.01, ***Very highly significant 
at P<0.001, SCA: Sickle cell anemia, SCT: Sickle cell trait, RBC: Red blood cell
Table 6: Clinical signs and symptoms among the study 














No 5 (15.6) 36 (72.0) 41 (50.0) <0.001***
Yes 27 (84.4) 14 (28.0) 41 (50.0)
Dyspnea
No 19 (59.4) 42 (84.0) 61 (74.4) 0.013*
Yes 13 (40.6) 8 (16.0) 21 (25.6)
Pallor
Yes 32 (100) 50 (100) 76 (92.7) 0.567
Icterus
No 16 (50.0) 43 (86.0) 59 (72.0) <0.001***
Yes 16 (50.0) 7 (14.0) 23 (28.0)
*Significant at P<0.05, **Highly significant at P<0.01, ***Very highly significant 
at P<0.001, SCA: Sickle cell anemia, SCT: Sickle cell trait










>9 g/dl 13 (26.0) 6 (18.8) 19 (23.2) 0.689
5–7 g/dl 19 (38.0) 12 (37.5) 31 (37.8)
7–9 g/dl 18 (36.0) 14 (43.8) 32 (39.0)
*Significant at P<0.05, **Highly significant at P<0.01, ***Very highly significant 
at P<0.001, Hb: Hemoglobin
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is very highly significant. This is also explained by the fact that in SCA 
there is more hemolysis and less production of adult Hb in comparison 
to SCT. Patients of SCA and with crisis had more anemia than patients 
of SCT and patients without crisis, due to amount of increased sickle 
hemoglobin [6].
Microalbuminuria is an important marker of glomerular injury in 
patients with SCA and may also be demonstrated in some SCT individuals. 
In the present study, in SCA, 50% cases had microalbuminuria 
and 28.1% had macroalbuminuria as compared to 24% and 14% in 
SCT patients, respectively. Among these data microalbuminuria shows 
significant p-value (0.015) when compared between SCA and SCT 
patients. The present study result shows a similarity with the studies 
by Guasch et al. [10]. In their prospective study by involving 300 adults 
aged 20–70 years, it was found that the prevalence of albuminuria 
was 68% in homozygous individuals versus 32% in heterozygous 
patients; in this latter study, 21% of the patients had RF. Sesso et al. in 
1998 found a high prevalence of microalbuminuria in Hb SS patients 
(30% vs. 8%, p<0.0001), mainly in those with a longer duration of 
disease (49% in patients older than 15 years) [11]. Aokai and Saad [12] 
shows that the prevalence rate of proteinuria in patients with Hb SS has 
been reported to vary from 17% to 33% in studies in which proteinuria 
was determined by the dipstick method. Alvarez et al. (2008) and 
Abbate et al. (2006) found that microalbuminuria and albuminuria were 
common in the SCD and could occur in up to 80% of patients resulting 
in a glomerulopathy [13,14]. For microalbuminuria in sickle cell crisis 
patients, the data have significant p-value (0.027) in our study. This 
suggests more patients in SCA with crisis had microalbuminuria than 
patients of SCT with crisis.
In the present study, out of 21 patients with sickle cell crisis, ten 
patients (48%) had significant albuminuria, among which nine 
patients (90%) were SCA cases and one patient (10%) was SCT case. 
Above finding suggest that albuminuria is common in sickle cell 
patients and there is more chance of getting it in SCA patients.
Painless hematuria (microscopic, macroscopic, or gross) is a common 
symptom	 of	 SCD.	Microscopic	 hematuria	was	 a	 predominant	 finding	
in SCA patients; 15 cases (46.87%) among the SCT, and eight patients 
(16%) in SCA had hematuria in our study. This data are significant 
having p value <0.05. In SCA patients with crisis, 11 patients (91.9%) 
had hematuria which was more than SCT patients with crisis, 
(n=2, 22.2%). This data have a p-value (0.001) and are very highly 
significant. The above findings suggest that hematuria occurred both in 
SCT and sickle cell anemia. But patients of SCA and with crisis had more 
number of cases of hematuria than SCT and with crisis because SCA had 
more glomerular and tubular dysfunction along with papillary necrosis 
and this pathology more severe in crisis cases.
Cast and crystals in urine were found in nine patients (28.12%) of SCA 
and 11 patients (22%) of SCT. Out of total population 9.7% had RBC 
casts, while 21.95% had granular casts. 31.2% of SCA patients and 12% 
of SCT patients had epithelial cells in urine. In our study, 58.3% of SCA 
patients with crisis had tubular epithelial cells in their urine. 50% of 
SCA patients and 77.78% of SCT patients with crisis had casts and 
crystals in urine. Casts were mostly granular cast, followed by RBC 
casts. p-value was found to be 0.01. Above finding suggests interstitial 
nephritis or glomerular or tubular damage in SCD patients. Wankhade 
et al. (2012) observed RBCs in 70%, epithelial cells in 96% patients 
Table 12: Prevalence of CKDs among the sickle cell patients in 
crisis










Normal 5 (41.7) 8 (88.88) 13 (61.90) 0.027*
CKD 7 (58.3) 1 (11.12) 8 (38.09)
*Significant at P<0.05, **Highly significant at P<0.01, ***Very highly significant 
at P<0.001, SCA: Sickle cell anemia, SCT: Sickle cell trait
Table 11: Prevalence of CKDs among the sickle cell patients










Normal 20 (62.5) 49 (98.0) 69 (84.1) <0.001***
CKD 12 (37.5) 1 (2.0) 13 (15.9)
*Significant at P<0.05, **Highly significant at P<0.01, ***Very highly significant 
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Fig. 3: Prevalence of chronic kidney diseases among the sickle cell 
patients
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in microscopic investigation of the urine of SCD. Renal tubular cells 
were observed in 40% patients while 11% patients were infected by 
bacteria. Yeasts were found in 9% urine samples. They also observed 
different normal and abnormal crystal in the urine sample of SCA [15]. 
We observed Tyrosine in 15%, cholesterol in 16%, phosphate in 40%, 
sulfamide in 11%, mucus in 2%, while hyline was found in 53% patients, 
uric acid in 34%, oxalate in 53%, and cystine in 5% SCA patients.
Hyposthenuria was a predominant finding in patients of sickle 
cell anemia. In SCA patients, 18 cases (56.2%) and in SCT 
patients 12 cases (24%) had hyposthenuria. In sickle cell crisis 
patients, 42.9% had developed hyposthenuria, out of which 58.33% 
were	 SCA	 patients	 and	 22.2%	were	 SCT	 patients.	 These	 findings	 are	
suggestive of renal medullary ischemia and the renal involvement is 
more in SCA patients than SCT patients, for which they were passing 
large amount of diluted urine, which would further contribute to the 
development of dehydration, leading to further renal ischemia and 
complications. Keitel et al. found that hyposthenuria is the most common 
complication associated with the presence of intravascular “S” Hb [16]. 
Sesso et al. found in their study urinary osmolality was reduced in 
patients with Hb SS or with Hb AS; however, it was particularly evident 
in Hb SS patients older than 15 years (median = 393 mosmol/kg, 
range = 366–469 mOsmol/kg) compared with Hb AS patients [11].
SCN is a spectrum of changes resulting from a cascade of events occurring 
in the kidney. This is triggered by red blood cell vascular occlusion, 
infarction and reperfusion injury occurring within the renal medullar, 
cortex, and collecting system. These may present as hyperfiltration, 
impaired urinary concentrating ability, albuminuria, decreased 
eGFR, and end-stage kidney disease [17]. In our study, we found 37.5% 
SCA patients having CKD and 2% SCT patients having CKD. This has a 
p-value of <0.001 and very highly significant. From this data it is derived 
that CKD is a common finding and highly associated in SCA in comparison 
to SCT. CKD is common in patients with SCD and its prevalence increases 
with age. At baseline, 28.6% of patients had CKD in Gosmanova et al. 
study [18]. Menye et al. in 2019 had the following observations. CKD was 
found in 16% patients in the SCA group and 11% in the SCT group. CKD 
was found in 37% of adult SCA patients [17]. However, a 50% prevalence 
of CKD in adult SCA was found in Bolarinwa et al. study in Nigeria [19].
Limitations
Small sample size is a limitation of our study and may not be 
representative of all the SCD population.
CONCLUSION
The prevalence of SCD is high in Western and Southern Odisha. In our 
study, we found that renal involvement is a common manifestation of 
SCD. Both the sickle cell patients with and without crisis were included 
in our study. Renal abnormalities were found to be more aggravated in 
crisis group. Interventions through early stage monitoring and detection 
may delay progression into advanced stages and end stage renal disease.
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